PO.ET09.10 · 实验与分子治疗
Tyrosine Kinase, Phosphatase, and Other Inhibitors
-
-
-
-
-
- 5868 5868 Proteomic analysis and efficacy evaluation reveal strong synergistic anti-leukemic activity of lasmotinib combined with menin inhibitors for AML An-Na Moon, Hee-sun Hwang, Ky-Youb Nam, KyungMin Cha, Sang Beom Lee, ChongChul Chai, Jinsun Kwon, Kyu-Tae Kim, June H. Han, Jeong Hyeok Yoon
- 5869 5869 Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration Paul Larsen, Tanna Bettendorf, Abiezer Blandon, Karyn Bouhana, Richard K. Brizendine, Eric Brown, LouAnn Cable, Mark J. Chicarelli, Michelle Crow, Brad Fell, John Fischer, Jennifer Fulton, Anna Guarnieri, Jackie Harrison, Leyla Haygood, Ravi Jalluri, Vijay Kumar, Cori A. Malinky, Maralee McVean, Rob Rieger, John Robinson, Lee Stunkard, Francis Sullivan, John I. Trujillo, Logan E. Vine, Shannon Winski, Yeyun Zhou
-
- 5871 5871 Discovery and characterization of firmonertinib, a novel EGFR inhibitor with broad activity against both EGFR classical and exon 20 insertion mutations Huibing Luo, Qing Li, Qiufeng Liu, Huayong Zhou, Yuting Sun, Jerry Y. Hsu, Luna Musib, Marcin Kowanetz, Stuart Lutzker, Zineb Mounir
-
-
- 5875 5875 Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models Bo Peng, Zhiyan Liang, Yan Xiong, Bingxing Wu, Shujie He, Zhou Yu, Guoqin Zhai, Dajun Yang, Yifan Zhai
- 5876 5876 Soluble TNF blockade as a strategy to enhance tyrosine-kinase inhibitor response and control metastatic burden in HER2-positive breast cancer Sofia Bruni, Marla Ladera, Camila Jencquel, Federico Waisberg, Martin A. Rivas, Roxana Schillaci, Maria Florencia Mercogliano
- 5877 5877 BH-30643, a novel macrocyclic non-covalent, mutant-selective EGFR inhibitor, addresses the resistance and potency limitations of contemporary EGFR TKIs Ping Jiang, Wei Deng, Nancy Ling, Danan Li, Zhenping Wang, Yue Hu, Joshua Choi, Eugene Rui, Geoffrey Oxnard, Jean Cui
-
-
-
-
- 5882 5882 Structure- and bioinformatics-driven development of a selective, orally bioavailable HER2 small molecule inhibitor (HM100714) for cancer therapy Ho Yeon Nam, Sun Young Jang, Jiyoung Jeon, HyungSeok Yoo, Jooyun Byun, Soonki Park, Soye Jeon, Haemin Chon, Yu-Yon Kim, Boram Kim, Young Gil Ahn
-
-
- 5885 5885 Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900 Bobby Kaghazchi, In Hwa Um, Amber Ortiz, Enrique Podarosu, David J. Harrison, Neil Carragher, Asier Unciti-Broceta
-
- 5887 5887 Profiling of reversible and covalent HER2 kinase inhibitors for anti-tumor activity and broader biological effects to evaluate selectivity and functional activity Luciano Galdieri, Steven Garner, Brogan Epkins, Emily Schultz, Daria Clucas, Pony (Yu-Ling) Lee, Chao-Di Chang, Chien-Chang Shen, Alastair J. King
-
-
